For example, increased Bcl-xL expression portends a worse prognosis in pancreatic cancer [4], thyroid cancer [5], follicular lymphoma [6], ovarian cancer [7],[8], hepatocellular carcinoma [9], and prostate cancer [10] and it has been specifically shown that increased levels of Bcl-xL correlate with treatment failure in thyroid cancer [5], ovarian cancer [8], and oropharyngeal cancer [11]. This evidence concerns the gene BCL2L1 and pancreatic neoplasm.